GCIA
DAWN

Gabelli & Co Investment Advisers’s Day One Biopharmaceuticals DAWN Stock Holding History

Gabelli & Co Investment Advisers’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.98M Buy
+325,350
New +$4.58M 1.03% 28

Other funds holding DAWN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Gabelli & Co Investment Advisers's DAWN Position: Q1 2026 in Review

Gabelli & Co Investment Advisers opened a new position in Day One Biopharmaceuticals (DAWN) in Q1 2026: 325,350 shares worth $6.98M. The stake represents 1.03% of the portfolio and ranks #28 among its holdings.

206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

  • Gabelli & Co Investment Advisers held 325,350 shares of Day One Biopharmaceuticals worth $6.98M as of Q1 2026.
  • Day One Biopharmaceuticals was a new Gabelli & Co Investment Advisers position in Q1 2026.
  • Day One Biopharmaceuticals made up 1.03% of Gabelli & Co Investment Advisers's portfolio in Q1 2026, its #28 holding.
  • 206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on Gabelli & Co Investment Advisers's 13F filing for Q1 2026, filed 14 May 2026.